236 related articles for article (PubMed ID: 25945063)
1. Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis.
Menon R; David BG
Clin Cosmet Investig Dermatol; 2015; 8():215-22. PubMed ID: 25945063
[TBL] [Abstract][Full Text] [Related]
2. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.
Dogra S; Uprety S; Suresh SH
Expert Opin Biol Ther; 2017 Mar; 17(3):395-402. PubMed ID: 28064543
[TBL] [Abstract][Full Text] [Related]
3. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
Bughani U; Saha A; Kuriakose A; Nair R; Sadashivarao RB; Venkataraman R; Patel S; Deshchougule AT; S SK; Montero E; Pai HV; Palanivelu DV; Melarkode R; Nair P
PLoS One; 2017; 12(7):e0180088. PubMed ID: 28672038
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India.
Budamakuntla L; Shree-Lakshmi HV; Bansal A; Venkatarayaraju SK
Psoriasis (Auckl); 2019; 9():19-27. PubMed ID: 31119094
[TBL] [Abstract][Full Text] [Related]
5. Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis.
Pai G; Pai AH
Case Rep Dermatol; 2017; 9(2):141-145. PubMed ID: 29033818
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.
Hernández P; Moreno E; Aira LE; Rodríguez PC
Curr Drug Targets; 2016; 17(6):666-77. PubMed ID: 26844560
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
Krupashankar DS; Dogra S; Kura M; Saraswat A; Budamakuntla L; Sumathy TK; Shah R; Gopal MG; Narayana Rao T; Srinivas CR; Bhat R; Shetty N; Manmohan G; Sai Krishna K; Padmaja D; Pratap DV; Garg V; Gupta S; Pandey N; Khopkar U; Montero E; Ramakrishnan MS; Nair P; Ganapathi PC
J Am Acad Dermatol; 2014 Sep; 71(3):484-92. PubMed ID: 24703722
[TBL] [Abstract][Full Text] [Related]
8. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.
Aira LE; López-Requena A; Fuentes D; Sánchez L; Pérez T; Urquiza A; Bautista H; Falcón L; Hernández P; Mazorra Z
MAbs; 2014; 6(3):783-93. PubMed ID: 24594862
[TBL] [Abstract][Full Text] [Related]
9. Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: Results from an expanded-access program.
Falcón Lincheta L; Saumell Nápoles Y; Gray Lovio OR; Viqueira Fuentesfría AM; Pérez Alonso T; Batista Romagoza M; Urquiza Rodríguez A; Mantecón Fernández B; Bautista Jerez HA; Fernández de Armas D; Martínez Matute ES; León García Y; Oramas Fernández DK; Marrero Chavez Y; Fernandez Lorente A; Valls Hung AR; Lorenzo-Luaces P; Valenzuela Silva C; Moreno E; Hernández-Casaña P
Int Immunopharmacol; 2024 Jun; 134():112225. PubMed ID: 38759368
[TBL] [Abstract][Full Text] [Related]
10. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.
Rodríguez PC; Prada DM; Moreno E; Aira LE; Molinero C; López AM; Gómez JA; Hernández IM; Martínez JP; Reyes Y; Milera JM; Hernández MV; Torres R; Avila Y; Barrese Y; Viada C; Montero E; Hernández P
Clin Exp Immunol; 2018 Feb; 191(2):229-239. PubMed ID: 28963724
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions.
Singh V
Dermatol Res Pract; 2016; 2016():1316326. PubMed ID: 27885324
[TBL] [Abstract][Full Text] [Related]
12. Itolizumab in Psoriasis.
Srivastava A
Indian J Dermatol; 2017; 62(4):418-421. PubMed ID: 28794555
[TBL] [Abstract][Full Text] [Related]
13. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.
Rodriguez PC; Torres-Moya R; Reyes G; Molinero C; Prada D; Lopez AM; Hernandez IM; Hernandez MV; Martinez JP; Hernandez X; Casaco A; Ramos M; Avila Y; Barrese Y; Montero E; Hernandez P
Results Immunol; 2012; 2():204-11. PubMed ID: 24371585
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD6 mAbs for the treatment of psoriasis.
Dogra S; D S; Rajagopalan M
Expert Opin Biol Ther; 2020 Oct; 20(10):1215-1222. PubMed ID: 32466689
[TBL] [Abstract][Full Text] [Related]
15. Erratum: Itolizumab - a humanized anti-CD6 monoclonal antibody with better side effects profile for the treatment of psoriasis [Corrigendum].
Clin Cosmet Investig Dermatol; 2015; 8():295. PubMed ID: 26082656
[No Abstract] [Full Text] [Related]
16. Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation.
Rambaldi B; Kim HT; Arihara Y; Asano T; Reynolds C; Manter M; Halpern M; Weber A; Koreth J; Cutler C; Gooptu M; Nikiforow S; Ho VT; Antin JH; Romee R; Ampudia J; Ng C; Connelly S; Soiffer RJ; Ritz J
Haematologica; 2022 Nov; 107(11):2617-2629. PubMed ID: 35484649
[TBL] [Abstract][Full Text] [Related]
17. Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab.
Caballero A; Filgueira LM; Betancourt J; Sánchez N; Hidalgo C; Ramírez A; Martinez A; Despaigne RE; Escalona A; Diaz H; Meriño E; Ortega LM; Castillo U; Ramos M; Saavedra D; García Y; Lorenzo G; Cepeda M; Arencibia M; Cabrera L; Domecq M; Estévez D; Valenzuela C; Lorenzo P; Sánchez L; Mazorra Z; León K; Crombet T
Clin Transl Immunology; 2020; 9(11):e1218. PubMed ID: 33304584
[TBL] [Abstract][Full Text] [Related]
18. Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience.
Budamakuntla L; Madaiah M; Sarvajnamurthy S; Kapanigowda S
Clin Exp Dermatol; 2015 Mar; 40(2):152-5. PubMed ID: 25495868
[TBL] [Abstract][Full Text] [Related]
19. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.
Díaz Y; Ramos-Suzarte M; Martín Y; Calderón NA; Santiago W; Viñet O; La O Y; Oyarzábal JPA; Pérez Y; Lorenzo G; Cepeda M; Saavedra D; Mazorra Z; Estevez D; Lorenzo-Luaces P; Valenzuela C; Caballero A; Leon K; Crombet T; Hidalgo CJ
Gerontology; 2020; 66(6):553-561. PubMed ID: 33105142
[TBL] [Abstract][Full Text] [Related]
20. Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.
Aira LE; Hernández P; Prada D; Chico A; Gómez JA; González Z; Fuentes K; Viada C; Mazorra Z
MAbs; 2016; 8(1):187-95. PubMed ID: 26466969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]